Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
NCT02550106 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136
Last updated 2020-02-25
Summary
Evaluate the proportion of patients with an urticaria control test \[UCT\] score of greater than or equal to 12 at Week 12.
Conditions
Interventions
- DRUG
-
OMALIZUMAB
sub cutaneous injections of 300 mg every 4 weeks until Week 8.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
CLAIRE BERNIER TAUGOURDEAU · HOPITAL HOTEL DIEU - NANTES CEDEX 1
-
PASCAL JOLY · HOPITAL CHARLES NICOLLE - ROUEN CEDEX
-
LUDOVIC MARTIN · HOTEL DIEU - ANGERS CEDEX 9
-
GERARD GUILLET · CHR LA MILETRIE - POITIERS CEDEX
-
PATRICE PLANTIN · CHI DE CORNOUAILLE - QUIMPER CEDEX
-
ALAIN DUPUY · HOPITAL PONTCHAILLOU - RENNES CEDEX 9
-
EVELYNE COLLET · CHU SITE DU BOCAGE - DIJON CEDEX
-
ANNICK BARBAUD · HOPITAUX DE BRABOIS - VANDOEUVRE LES NANCY CEDEX
-
ZIAD REGUIAI · HOPITAL ROBERT DEBRE - REIMS CEDEX
-
FABIEN PELLETIER · HOPITAL JEAN MINJOZ - BESANCON CEDEX
-
DELPHINE STAUMONT SALLE · HOPITAL CLAUDE HURIEZ- LILLE CEDEX
-
JULIETTE JEGOU · CH DE CHALONS EN CHAMPAGNE - CHALONS EN CHAMPAGNE CEDEX
-
EMMANUELLE AMSLER · HOPITAL TENON - PARIS CEDEX 20
-
OLIVIER CHOSIDOW · HOPITAL HENRI MONDOR - CRETEIL
-
VINCENT DESCAMPS · HOPITAL BICHAT CLAUDE BERNARD - PARIS CEDEX 18
-
EMMANUEL MAHE · CH VICTOR DUPOUY - ARGENTEUIL CEDEX
-
LILIANE LAROCHE · HOPITAL AVICENNE - BOBIGNY CEDEX
-
GERMAINE GABISON · HOPITAL SAINT LOUIS - PARIS CEDEX 10
-
SELIM ARACTINGI · HOPITAL COCHIN - PARIS
-
LAURENCE BOUILLET · CHU DE GRENOBLE - LA TRONCHE
-
JEAN-JACQUES GROB · HOPITAL TIMONE - MARSEILLE CEDEX 05
-
FREDERIC CAMBAZARD · CHU SAINT ETIENNE - ST PRIEST EN JAREZ CEDEX
-
THIERRY BOYE · HIA SAINTE ANNE - TOULON CEDEX 9
-
JEAN-PHILIPPE LACOUR · HOPITAL DE L'ARCHET - NICE CEDEX 3
-
PHILIPPE BERBIS · HOPITAL NORD- MARSEILLE
-
LAURENT MEUNIER · HOPITAL CAREMEAU - NIMES CEDEX 9
-
FRANCOISE GIORDANO LABADIE · HOPITAL LARREY - TOULOUSE CEDEX 9
-
NADIA RAISON PEYRON · HOPITAL ST ELOI - MONTPELLIER CEDEX 5
-
MARIE CHRISTINE FERRIER LE BOUEDEC · CHU ESTAING - CLERMONT FERRAND
-
MARIE SYLVIE DOUTRE · HOPITAL DE HAUT LEVEQUE - PESSAC CEDEX
-
BRIGITTE MILPIED · HOPITAL ST ANDRE - BORDEAUX CEDEX
-
CHRISTOPHE BEDANE · HOPITAL DUPUYTREN - LIMOGES CEDEX 1
-
PHILIPPE MODIANO · HOPITAL ST VINCENT DE PAUL - LILLE CEDEX
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-22
- Primary Completion
- 2016-01-11
- Completion
- 2016-01-11
Countries
- France
Study Locations
More Related Trials
-
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
NCT01803763 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
NCT01713725 ·Status: COMPLETED ·Phase: PHASE2
-
Cold Urticaria Treatment With Xolair
NCT01580592 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
NCT01264939 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
NCT00866788 ·Status: COMPLETED ·Phase: PHASE2
-
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
NCT02814630 ·Status: COMPLETED ·Phase: NA
-
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
NCT01599637 ·Status: COMPLETED ·Phase: PHASE2
-
Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria
NCT04583475 ·Status: COMPLETED
-
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
NCT01723072 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
NCT02191072 ·Status: UNKNOWN ·Phase: NA
-
Efficacy Study of Omalizumab in Cholinergic Urticaria
NCT02012387 ·Status: COMPLETED ·Phase: PHASE2
-
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
NCT06365879 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Anti-IgE in Chronic Urticaria
NCT00130234 ·Status: COMPLETED ·Phase: PHASE2
-
Real Life Use of Omalizumab in Chronic Urticaria
NCT04584190 ·Status: UNKNOWN
-
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
NCT05916937 ·Status: RECRUITING ·Phase: PHASE4
-
Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients
NCT02329223 ·Status: COMPLETED ·Phase: PHASE3
-
Omalizumab in Severe and Refractory Solar Urticaria
NCT02262130 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Molecular Endotypes of Chronic Idiopathic Urticaria
NCT04774315 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
NCT04944602 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
NCT02166151 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
NCT03580356 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
NCT02392624 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
NCT03580369 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
NCT02477332 ·Status: COMPLETED ·Phase: PHASE2